Trevena Inc TRVN:NASDAQ

RT Quote | NASDAQ | USD
Last | 08/18/22 EDT
0.2311quote price arrow down-0.0139 (-5.6735%)
Volume
1,722,259
52 week range
0.18 - 1.40
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.2311
  • 52 Week High1.40
  • 52 Week High Date09/02/21
  • 52 Week Low0.18
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap40.14M
  • Shares Out173.68M
  • 10 Day Average Volume1.58M
  • Dividend-
  • Dividend Yield-
  • Beta1.74
  • YTD % Change-60.33

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.2311
  • 52 Week High1.40
  • 52 Week High Date09/02/21
  • 52 Week Low0.18
  • 52 Week Low Date05/11/22
  • Market Cap40.14M
  • Shares Out173.68M
  • 10 Day Average Volume1.58M
  • Dividend-
  • Dividend Yield-
  • Beta1.74
  • YTD % Change-60.33

RATIOS/PROFITABILITY

  • EPS (TTM)-0.36
  • P/E (TTM)-0.65
  • Fwd P/E (NTM)-0.69
  • EBITDA (TTM)-58.742M
  • ROE (TTM)-93.47%
  • Revenue (TTM)200,000.00
  • Gross Margin (TTM)-378.00%
  • Net Margin (TTM)-29,547.00%
  • Debt To Equity (MRQ)37.49%

EVENTS

  • Earnings Date11/14/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Trevena Inc

There is no recent news for this security.

Profile

MORE
Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in...
Leon Moulder Jr.
Independent Chairman of the Board
Carrie Bourdow
President, Chief Executive Officer, Director
Barry Shin J.D.
Chief Financial Officer, Senior Vice President
Address
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA
19087
United States

Top Peers

SYMBOLLASTCHG%CHG
ACRX
AcelRx Pharmaceuticals Inc
0.325+0.0195+6.38%
ZYNE
Zynerba Pharmaceuticals Inc
1.30-0.02-1.52%
ADMP
Adamis Pharmaceuticals Corp
0.3332+0.0031+0.94%
AVTX
Avalo Therapeutics Inc
4.92-0.15-2.96%
CYTH
Cyclo Therapeutics Inc
2.66+0.11+4.31%